Pardes Biosciences, Inc. (PRDS) Financial Statements (2024 and earlier)

Company Profile

Business Address 2173 SALK AVENUE
CARLSBAD, CA 92008
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

6/30/2023
MRQ
12/31/2022
12/31/2021
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:197,300,000268,678,000
Cash and cash equivalents59,284,000268,678,000
Short-term investments138,056,000 
Other undisclosed cash, cash equivalents, and short-term investments(40,000) 
Prepaid expense3,062,0006,581,000
Debt securities, available-for-sale, accrued interest, after allowance for credit loss300,000 
Other undisclosed current assets(260,000) 
Total current assets:200,402,000275,259,000
Noncurrent Assets
Other noncurrent assets 219,000 
Total noncurrent assets: 219,000 
TOTAL ASSETS:200,621,000275,259,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20,425,0008,965,000
Accounts payable4,929,0002,385,000
Accrued liabilities15,496,0006,580,000
Total current liabilities:20,425,0008,965,000
Noncurrent Liabilities
Total liabilities:20,425,0008,965,000
Equity
Equity, attributable to parent180,196,000266,294,000
Common stock6,0006,000
Additional paid in capital328,372,000317,812,000
Accumulated other comprehensive income (loss)(24,000) 
Accumulated deficit(148,158,000)(51,524,000)
Total equity:180,196,000266,294,000
TOTAL LIABILITIES AND EQUITY:200,621,000275,259,000

Income Statement (P&L) (USD)

6/30/2023
TTM
12/31/2022
12/31/2021
Operating expenses(99,817,000)(38,488,000)
Other undisclosed operating income  76,976,000
Operating income (loss):(99,817,000)38,488,000
Income (loss) from continuing operations:(99,817,000)38,488,000
Income (loss) before gain (loss) on sale of properties:38,488,000
Net income (loss):(99,817,000)38,488,000
Other undisclosed net income (loss) attributable to parent3,183,000(77,006,000)
Net loss available to common stockholders, diluted:(96,634,000)(38,518,000)

Comprehensive Income (USD)

6/30/2023
TTM
12/31/2022
12/31/2021
Net income (loss):(99,817,000)38,488,000
Other comprehensive income (loss)(24,000) 
Other undisclosed comprehensive loss  
Comprehensive income (loss):(99,841,000)38,488,000
Other undisclosed comprehensive income, net of tax, attributable to parent3,183,000 
Comprehensive income (loss), net of tax, attributable to parent:(96,658,000)38,488,000

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: